Adults 18 to 75, any sex, with Chronic Hand Dermatitis. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Percent Change From Baseline in Modified Total Lesion Symptom Score (mTLSS)Primary· 16 weeks
Percent change from baseline in hand mTLSS at Week 16. The mTLSS is an assessment of the severity of each of the following: erythema, scaling, lichenification/hyperkeratosis, vesicles, edema, fissures, and pruritus/pain. Each of these are rated using a 4-point severity scale. The ratings are added to create a total mTLSS calculated as the sum of assigned individual scores with a maximum value of 21 (most severe disease) and a minimum of 0 (no disease)
Group
Value
95% CI
ASN002 40 mg
-49.5
± 40.65
ASN002 80 mg
-71.3
± 26.97
Placebo Oral Tablet
-29.9
± 38.51
Change From Baseline in Hand Physician Global Assessment (PGA)Secondary· 16 weeks
Proportion of participants with a response of Physicians Global Assessment achieving clear (0) or almost clear (1)
Group
Value
95% CI
ASN002 40 mg
7
ASN002 80 mg
10
Placebo Oral Tablet
2
Change From Baseline in Hand Patient Global Assessment (PaGA)Secondary· 16 weeks
Reduction of PaGA compared to baseline where marked improvement was noted with at least 75% clear
Group
Value
95% CI
ASN002 40 mg
7
ASN002 80 mg
7
Placebo Oral Tablet
2
Adverse events — posted to ClinicalTrials.gov
Time frame: 16 weeks.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
NCT03654755 — Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
· Phase 2
· terminated
NCT03531957 — Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis (RADIANT)
· Phase 2
· completed
NCT03139981 — A Study To Evaluate ASN002 In Subjects With Atopic Dermatitis
· Phase 1
· completed
Other Asana BioSciences trials
Trials by the same sponsor.
NCT03798561 — Study to Evaluate ASN008 Topical Gel (TG)
· Phase 1
· completed
NCT03641573 — Phase 1 Study to Evaluate ASN002 Absorption, Metabolism, and Excretion of [14C] Following a Single Oral Dose in Healthy
· Phase 1
· completed
NCT03654755 — Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
· Phase 2
· terminated
NCT03531957 — Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis (RADIANT)
· Phase 2
· completed
NCT03415126 — A Study of ASN007 in Patients With Advanced Solid Tumors
· Phase 1
· completed
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Asana BioSciences
Last refreshed: 9 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03728504.